title: [Chemotherapy-induced neuropathy].
abstract: BACKGROUND
  Neurological sequelae of cytostatic chemotherapy are a growing medical problem as the number of patients suffering from malignant diseases is steadily increasing.
  
  
  OBJECTIVE
  Chemotherapy-induced neuropathies (CIN) are among the most common side effects of many cytostatic drugs. Awareness of symptoms, diagnosis and treatment of these conditions are therefore highly relevant.
  
  
  METHODS
  A review of the primary and secondary literature was carried out.
  
  
  RESULTS
  This article reviews the literature on neuropathies induced by frequently used cytostatic drugs and discusses diagnostic, preventive and therapeutic strategies. Specifically, this review focuses on antibody-drug conjugates, platinum-based antineoplastic drugs, proteasome inhibitors, taxanes and vinca alkaloids. The lack of well-established preventive and therapeutic strategies complicates the management of CINs. The most successful approaches to CIN prevention are modifications of the treatment regime including single and cumulative doses, frequency and mode of infusion. Current evidence favors duloxetine as a symptomatic treatment of platinum-induced neuropathies.
  
  
  CONCLUSIONS
  The CINs are an unsolved medical problem. Knowledge of symptoms as well as preventive, diagnostic and therapeutic strategies is important when patients present in clinical practice with neurological symptoms following chemotherapy.
authors.affiliation: Klinik und Hochschulambulanz für Neurologie mit Lehrstuhl für Experimentelle Neurologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland, wolfgang.boehmerle@charite.de.
authors.forename: W
authors.initials: W
authors.lastname: Boehmerle
authors.forename: P
authors.initials: P
authors.lastname: Huehnchen
authors.forename: M
authors.initials: M
authors.lastname: Endres
mesh_terms: D000700:Analgesics / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000068736:Duloxetine Hydrochloride; D019317:Evidence-Based Medicine; D006801:Humans; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000970:Antineoplastic Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride